Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06686394). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 181 participants (ESTIMATED). Conditions: Breast Neoplasms, Breast Cancer. Interventions: BIOLOGICAL: Patritumab deruxtecan; BIOLOGICAL: Trastuzumab; BIOLOGICAL: Trastuzumab Biosimilar; BIOLOGICAL: Pertuzumab; BIOLOGICAL: Tucatinib. Primary outcome measures: Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT) , Up to 21 days; Part 1: Number of Participants with One or More Adverse Events (AEs) , Up to approximately 36 months; Part 1: Number of Participants who Discontinue Study Intervention Due to an AE , Up to approximately 12 months; Part 2: Objective Response Rate (ORR) , Up to approximately 36 months. Brief summary: Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment